Genetic Indicators for Likelihood of Secondary Adulthood Cancer

According to a new study, two genetic variations may exist that would predict which childhood Hodgkin’s lymphoma patients are at highest risk for secondary cancer in adulthood. The purpose of the study was to point out that despite the fact that Hodgkin’s lymphoma is one of the most treatable cancers around, pediatric survivors tend to face more of a risk for radiation-therapy induced second malignant neoplasms.

Kenan Onel, MD, PhD, associate professor of pediatrics at the University of Chicago, Illinois, and senior author of the study expounded on the findings:

"The idea is that different exposures elicit different cellular responses, each with its own set of genetic determinants," he told Medscape Medical News. "Thus, by not accounting for them in GWASs, you are by definition going to obscure and attenuate disease-related genetic signals.

"Thus, in the absence of exposure information, they will appear neutral in genetic studies and not be identified," he added. "Our risk variants seem to be associated with risk for second cancers in Hodgkin's lymphoma patients treated under the age of 20, but not over the age of 20," he said, "and the average time to development of a second cancer is about 20 years.

"The next step is to identify more patients to study so that we can have more confidence in the clinical value of our findings," Dr. Onel explained. "Data from Stanford University suggest that some subsets of patients with Hodgkin's lymphoma can be successfully cured with chemotherapy alone, so there are radiation-therapy-free options.

"If the patient does need radiation, then the presence of the risk variants may suggest that the patients be closely monitored for second cancer, much the same way as a patient with a BRCA mutation would be followed," he pointed out.

"All of this is in the future of course," he added, "assuming our results stand up to further scrutiny."

The study was published online July 24 in Nature Medicine.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap